Ascorbate supplement reduces oxidative stress in dyslipidemic patients undergoing apheresis

Chiang Ting Chien, Wei Tien Chang, Heui Wen Chen, Tzung Dau Wang, Shaw Yih Liou, Tzay Jinn Chen, Yen Lin Chang, Yuan Teh Lee, Su Ming Hsu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective-The effect of ascorbate treatment on apheresis-induced oxidative stress in uremic and dyslipidemic patients was evaluated. Methods and Results-We developed a chemiluminescence-emission spectrum and high-performance liquid chromatography analysis to assess the effect of ascorbate supplement on plasma reactive oxygen species (ROS) scavenging activity and oxidized lipid/protein production in hyperlipidemic and uremic patients undergoing apheresis. Apheresis was efficient in reduction of atherogenic lipoproteins, complement, fibrinogen, soluble intercellular adhesion molecule-1, and oxidative parameters including phosphatidylcholine hydroperoxide (PCOOH), malonaldehyde, methylguanidine, and diotyrosine. Apheresis itself, however, activated leukocytes to increase ROS activity and reduced the plasma ROS scavenging activity. Ascorbate administration selectively diminished apheresis-enhanced H2O2 and inflammatory mediators such as tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1. Chronically dyslipidemic and uremic patients undergoing biweekly apheresis plus ascorbate treatment had lower levels of C-reactive protein and PCOOH than did those without ascorbate treatment during a 6-month follow-up study period. Conclusions-We demonstrate that apheresis with ascorbate treatment provides a therapeutic potential in reducing atherosclerotic risk via inhibition of H2O2-induced oxidative stress in patients with uremia or dyslipidemia.

Original languageEnglish
Pages (from-to)1111-1117
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume24
Issue number6
DOIs
Publication statusPublished - 2004 Jun 1

Fingerprint

Blood Component Removal
Oxidative Stress
Reactive Oxygen Species
Methylguanidine
Therapeutics
Chemokine CCL2
Uremia
Intercellular Adhesion Molecule-1
Dyslipidemias
Luminescence
Malondialdehyde
C-Reactive Protein
Fibrinogen
Lipoproteins
Leukocytes
Tumor Necrosis Factor-alpha
High Pressure Liquid Chromatography
Lipids
phosphatidylcholine hydroperoxide

Keywords

  • Apheresis
  • Atherosclerosis
  • Dialysis
  • Reactive oxygen species
  • Vitamin C

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ascorbate supplement reduces oxidative stress in dyslipidemic patients undergoing apheresis. / Chien, Chiang Ting; Chang, Wei Tien; Chen, Heui Wen; Wang, Tzung Dau; Liou, Shaw Yih; Chen, Tzay Jinn; Chang, Yen Lin; Lee, Yuan Teh; Hsu, Su Ming.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 24, No. 6, 01.06.2004, p. 1111-1117.

Research output: Contribution to journalArticle

Chien, Chiang Ting ; Chang, Wei Tien ; Chen, Heui Wen ; Wang, Tzung Dau ; Liou, Shaw Yih ; Chen, Tzay Jinn ; Chang, Yen Lin ; Lee, Yuan Teh ; Hsu, Su Ming. / Ascorbate supplement reduces oxidative stress in dyslipidemic patients undergoing apheresis. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2004 ; Vol. 24, No. 6. pp. 1111-1117.
@article{60f98c080aa8477481b01786b91fe9bc,
title = "Ascorbate supplement reduces oxidative stress in dyslipidemic patients undergoing apheresis",
abstract = "Objective-The effect of ascorbate treatment on apheresis-induced oxidative stress in uremic and dyslipidemic patients was evaluated. Methods and Results-We developed a chemiluminescence-emission spectrum and high-performance liquid chromatography analysis to assess the effect of ascorbate supplement on plasma reactive oxygen species (ROS) scavenging activity and oxidized lipid/protein production in hyperlipidemic and uremic patients undergoing apheresis. Apheresis was efficient in reduction of atherogenic lipoproteins, complement, fibrinogen, soluble intercellular adhesion molecule-1, and oxidative parameters including phosphatidylcholine hydroperoxide (PCOOH), malonaldehyde, methylguanidine, and diotyrosine. Apheresis itself, however, activated leukocytes to increase ROS activity and reduced the plasma ROS scavenging activity. Ascorbate administration selectively diminished apheresis-enhanced H2O2 and inflammatory mediators such as tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1. Chronically dyslipidemic and uremic patients undergoing biweekly apheresis plus ascorbate treatment had lower levels of C-reactive protein and PCOOH than did those without ascorbate treatment during a 6-month follow-up study period. Conclusions-We demonstrate that apheresis with ascorbate treatment provides a therapeutic potential in reducing atherosclerotic risk via inhibition of H2O2-induced oxidative stress in patients with uremia or dyslipidemia.",
keywords = "Apheresis, Atherosclerosis, Dialysis, Reactive oxygen species, Vitamin C",
author = "Chien, {Chiang Ting} and Chang, {Wei Tien} and Chen, {Heui Wen} and Wang, {Tzung Dau} and Liou, {Shaw Yih} and Chen, {Tzay Jinn} and Chang, {Yen Lin} and Lee, {Yuan Teh} and Hsu, {Su Ming}",
year = "2004",
month = "6",
day = "1",
doi = "10.1161/01.ATV.0000127620.12310.89",
language = "English",
volume = "24",
pages = "1111--1117",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Ascorbate supplement reduces oxidative stress in dyslipidemic patients undergoing apheresis

AU - Chien, Chiang Ting

AU - Chang, Wei Tien

AU - Chen, Heui Wen

AU - Wang, Tzung Dau

AU - Liou, Shaw Yih

AU - Chen, Tzay Jinn

AU - Chang, Yen Lin

AU - Lee, Yuan Teh

AU - Hsu, Su Ming

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Objective-The effect of ascorbate treatment on apheresis-induced oxidative stress in uremic and dyslipidemic patients was evaluated. Methods and Results-We developed a chemiluminescence-emission spectrum and high-performance liquid chromatography analysis to assess the effect of ascorbate supplement on plasma reactive oxygen species (ROS) scavenging activity and oxidized lipid/protein production in hyperlipidemic and uremic patients undergoing apheresis. Apheresis was efficient in reduction of atherogenic lipoproteins, complement, fibrinogen, soluble intercellular adhesion molecule-1, and oxidative parameters including phosphatidylcholine hydroperoxide (PCOOH), malonaldehyde, methylguanidine, and diotyrosine. Apheresis itself, however, activated leukocytes to increase ROS activity and reduced the plasma ROS scavenging activity. Ascorbate administration selectively diminished apheresis-enhanced H2O2 and inflammatory mediators such as tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1. Chronically dyslipidemic and uremic patients undergoing biweekly apheresis plus ascorbate treatment had lower levels of C-reactive protein and PCOOH than did those without ascorbate treatment during a 6-month follow-up study period. Conclusions-We demonstrate that apheresis with ascorbate treatment provides a therapeutic potential in reducing atherosclerotic risk via inhibition of H2O2-induced oxidative stress in patients with uremia or dyslipidemia.

AB - Objective-The effect of ascorbate treatment on apheresis-induced oxidative stress in uremic and dyslipidemic patients was evaluated. Methods and Results-We developed a chemiluminescence-emission spectrum and high-performance liquid chromatography analysis to assess the effect of ascorbate supplement on plasma reactive oxygen species (ROS) scavenging activity and oxidized lipid/protein production in hyperlipidemic and uremic patients undergoing apheresis. Apheresis was efficient in reduction of atherogenic lipoproteins, complement, fibrinogen, soluble intercellular adhesion molecule-1, and oxidative parameters including phosphatidylcholine hydroperoxide (PCOOH), malonaldehyde, methylguanidine, and diotyrosine. Apheresis itself, however, activated leukocytes to increase ROS activity and reduced the plasma ROS scavenging activity. Ascorbate administration selectively diminished apheresis-enhanced H2O2 and inflammatory mediators such as tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein-1. Chronically dyslipidemic and uremic patients undergoing biweekly apheresis plus ascorbate treatment had lower levels of C-reactive protein and PCOOH than did those without ascorbate treatment during a 6-month follow-up study period. Conclusions-We demonstrate that apheresis with ascorbate treatment provides a therapeutic potential in reducing atherosclerotic risk via inhibition of H2O2-induced oxidative stress in patients with uremia or dyslipidemia.

KW - Apheresis

KW - Atherosclerosis

KW - Dialysis

KW - Reactive oxygen species

KW - Vitamin C

UR - http://www.scopus.com/inward/record.url?scp=2942577469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942577469&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.0000127620.12310.89

DO - 10.1161/01.ATV.0000127620.12310.89

M3 - Article

C2 - 15072991

AN - SCOPUS:2942577469

VL - 24

SP - 1111

EP - 1117

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 6

ER -